Statera Biopharma, Inc. STAB
At closeNov 3, 2026, 4:00 PM EST
- YTD
- -33.33%
- 1 year
- +100.00%
- Market cap
- 14.28K
- Revenue (ttm)
- 3.69M
- EPS (ttm)
- -0.79
- Shares out
- 54.66M
- YTD return
- -33.33%
- 1-year return
- +100.00%
- Volume
- 700
- Avg volume
- 25.18K
- Open
- 0.0001
- Previous close
- 0.0002
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0266
- Earnings date
- Jan 1, 2024
2Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 9.10M
- PEG ratio
- 0.00
- Price / sales
- 0.44
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 183.50%
- Free cash flow
- 340.10K
- Total cash
- 506.10K
- Total debt
- 7.41M
- Return on equity
- -286.94%
- Short % of float
- 1.65%
- 50-day average
- 0.076158
- 200-day average
- 0.168793
Next earnings
Jan 1, 2024
Expected Jan 1, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 1, 2024 | Sep 1, 2023 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | 0.00 | -0.07 | — | — |
| Nov 15, 2021 | Sep 1, 2021 | 0.00 | -0.47 | — | — |
About Statera Biopharma, Inc.
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- staterabiopharma.com
News
CLARIANE BNP Paribas Primary New Issues: NO STAB Notice 
NEOPHARMED - BNP Paribas Primary New Issues: NO STAB Notice 
BNP Paribas Primary New Issues: STAB Notice 
BNP Paribas Primary New Issues: STAB Notice - BioGroup 
BNP Paribas Primary New Issues: No STAB Notice - HOMEVI 
BNP Paribas Primary New Issues: No STAB Notice - Lutech 
BNP Paribas Primary New Issues: Post-STAB Notice - No Stab NEW IMMO HOLDING 
CLARIANE BNP Paribas Primary New Issues: NO STAB Notice 
AZELIS - BNP Paribas Primary New Issues: NO STAB Notice 
BNP Paribas Primary New Issues: POST STAB NOTICE - NO STAB - EUTELSAT COMMUNICATIONS
Your note
Sign in to keep a note on STAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARONSTAM PETER | Chief Financial Officer | Stock Award(Grant) | Jul 26, 2021 | 141,370 |
| BARBARICK STEVE K | Director | Stock Award(Grant) | Sep 8, 2021 | 60,000 |
| BUCKHEIT ROBERT | Chief Technology Officer | Stock Award(Grant) | Jul 26, 2021 | 24,378 |
| HANDLEY MICHAEL K | Chief Executive Officer | Stock Award(Grant) | Jul 26, 2021 | 296,609 |
| MARKVICKA TAUNIA | Chief Operating Officer | Stock Award(Grant) | Sep 27, 2021 | 100,000 |
| MCAVOY COZETTE M | Officer | Stock Award(Grant) | Jul 26, 2021 | 60,947 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 2.48% | 1,356,946 | 40.71K | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 0.69% | 378,677 | 11.36K | Sep 29, 2022 |
| Northern Trust Corporation | 0.31% | 171,110 | 5.13K | Sep 29, 2022 |
| Geode Capital Management, LLC | 0.24% | 130,774 | 3.92K | Sep 29, 2022 |
| Blackrock Inc. | 0.20% | 111,751 | 3.35K | Sep 29, 2022 |
| Virtu Financial LLC | 0.19% | 102,385 | 3.07K | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.69% | 378,677 | 11.36K | Sep 29, 2022 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.20% | 108,153 | 3.24K | Dec 30, 2022 |
| SunAmerica Series Trust-SA T. Rowe Price Asset Allocation Growth Port | 0.11% | 61,200 | 1.83K | Oct 30, 2022 |
| Fidelity Extended Market Index Fund | 0.10% | 54,957 | 1.65K | Nov 29, 2022 |
| Fidelity Series Total Market Index Fund | 0.05% | 26,219 | 786 | Nov 29, 2022 |
| Fidelity Total Market Index Fund | 0.04% | 22,064 | 661 | Nov 29, 2022 |